← Eichor
Study identifier: NCT06522581 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy

Condition: Hypoxic Ischemic Encephalopathy of Newborn  ·  Sponsor: Armed Forces Hospital, Pakistan

PhasePhase 1
Planned participants200
Who can joinAll sexes, 1 Day to 30 Days
Healthy volunteersNo

About this study

Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.

This description comes directly from the study's public registry record.

Talk to the study team

arshad Khushdil  ·  03463300030  ·  drarshad104589@yahoo.com

arshad Khushdil  ·  03463300030

Always discuss trial participation with your own doctor first.

Locations (1)

MHRawalpindi, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06522581